START Barcelona-Hospital HM Nou Delfos

Barcelona 8023

6 studies enrolling now · 9 studies all time

What they study most

Acute Myeloid Leukemia, Advanced Hematologic Tumors, Advanced Lung Carcinoma, Advanced Solid Tumors, Cholangiocarcinoma, Colorectal Cancer, FGFR2 Amplification, FGFR2 Gene Activation, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Mutation, FGFR2 Gene Translocation, HER2 Amplification

Studies at this site

• Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors — Recruiting now
• A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement — Recruiting now
• Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment — Recruiting now
• Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment — Recruiting now
• A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors — Recruiting now
• Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer — Recruiting now
• A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors — Stopped early
• REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors — Completed
• ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer — Running, not enrolling